Hepatic Encephalopathy Treatment Market Report and Forecast 2024-2032

Hepatic Encephalopathy Treatment Market Report and Forecast 2024-2032


Hepatic Encephalopathy Treatment Market Report and Forecast 2024-2032

Hepatic Encephalopathy Treatment Market Outlook

The hepatic encephalopathy treatment market size was valued at USD 1.65 billion in 2023, driven by increasing incidence of liver cirrhosis across the major markets. The market size is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032 to achieve a value of USD 2.68 billion by 2032.

Hepatic Encephalopathy: Introduction

Hepatic encephalopathy is a neurological disorder stemming from liver dysfunction, often due to chronic liver disease like cirrhosis. It disrupts the brain's function, leading to a spectrum of symptoms ranging from mild cognitive impairments to deep coma. The condition arises when the liver fails to remove toxins from the blood, allowing substances like ammonia to accumulate and harm brain cells. Management involves treating the underlying liver condition and reducing blood toxin levels.

Key Trends in the Hepatic Encephalopathy Treatment Market

The hepatic encephalopathy (HE) treatment market is influenced by various factors, with key trends shaping its landscape. Enhanced diagnostic tools enable early and more accurate detection of HE. Technologies like blood ammonia level detection, MRI, and CT scans are becoming more sophisticated, aiding in the timely treatment of the condition. The global increase in liver diseases, including cirrhosis and hepatitis, is leading to a higher incidence of hepatic encephalopathy. This trend is driving demand for effective HE treatment options.

Pharmaceutical and biotech companies are investing in R&D to develop novel therapeutics for HE. There's a focus on creating treatments that are more effective, have fewer side effects, and offer easier administration. There's a growing awareness about liver health and HE among the general population. This, coupled with increased healthcare spending in many countries, is leading to better access to treatment options.

Treatment of HE is evolving from traditional methods to more comprehensive, multimodal strategies. This includes the use of dietary management, medications, and in severe cases, liver transplantation. There's a growing interest in using probiotics and other non-pharmacological treatments to manage HE. These methods are being researched for their potential to improve gut health and reduce the production of toxins that can contribute to HE.

Advances in genomics and bioinformatics are paving the way for personalized treatment approaches. Predictive analytics are being used to understand patient risk profiles and tailor treatments accordingly.

Regulatory bodies are providing support for HE treatment development through fast-track designations, funding for research, and guidance on clinical trial designs. This is encouraging innovation and speeding up the process of bringing new treatments to the market.

Hepatic Encephalopathy Treatment Market Segmentation

Market Breakup by Drug Class
  • Antibiotics
  • Laxatives
  • L-ornithine
  • L-aspartate
  • Others
Market Breakup by Diagnosis
  • Blood Tests
  • CT Scan
  • Liver Functioning Tests (LFT)
  • Others
Market Breakup by Treatment
  • Medication
  • Surgery
  • Others
Market Breakup by Route of Administration
  • Oral
  • Injectable
  • Intravenous
  • Rectal
  • Others
Market Breakup by End User
  • Hospitals
  • Homecare
  • Speciality Clinics
  • Others
Market Breakup by Distribution Channels
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Hepatic Encephalopathy Treatment Market Overview

North America shows a comprehensive approach to treatment, with advanced healthcare facilities and widespread use of medications like lactulose and rifaximin. The U.S. leads in adopting new therapies and investing in liver disease research.Europe, characterized by strong healthcare systems and a focus on evidence-based treatments. Countries like Germany, the UK, and France actively integrate dietary management and pharmacotherapy in Hepatic Encephalopathy treatment protocols.

Japan is experiencing rapid growth due to increasing liver disease prevalence. The region is embracing both traditional and modern treatment approaches, with growing healthcare investments improving access to advanced therapies.

Hepatic Encephalopathy Treatment Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Salix Pharmaceuticals
  • Mallinckrodt plc.
  • Merck & Co., Inc.
  • Bausch Health
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson Services, Inc.
  • Eisai Co., Ltd
  • AbbVie Inc.
  • Hikma Pharmaceuticals PLC
  • Vedanta Biosciences
  • Patricia Bloom
  • Umecrine Cognition
  • Axcella Health Inc.
  • Pfizer Inc.
  • Rebiotix
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Hepatic Encephalopathy Treatment Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Hepatic Encephalopathy Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3.1 Germany Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3.2 France Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3.3 Italy Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3.4 Spain Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.4 Japan Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
6 Hepatic Encephalopathy Treatment Market Overview – 7MM
6.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023)
6.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
7 Hepatic Encephalopathy Treatment Market Landscape – 7MM
7.1 Amyotrophic Lateral Sclerosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Hepatic Encephalopathy Treatment Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Treatment
7.2.3 Analysis by Route of Administration
8 Hepatic Encephalopathy Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Hepatic Encephalopathy Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Hepatic Encephalopathy Treatment Market Segmentation – 7MM
11.1 Hepatic Encephalopathy Treatment Market by Drug Class
11.1.1 Market Overview
11.1.2 Antibiotics
11.1.3 Laxatives
11.1.4 L-ornithine
11.1.5 L-aspartate
11.1.6 Others
11.2 Hepatic Encephalopathy Treatment Market by Diagnosis
11.2.1 Market Overview
11.2.2 Blood Tests
11.2.3 CT Scan
11.2.4 Liver Functioning Tests (LFT)
11.2.5 Others
11.3 Hepatic Encephalopathy Treatment Market by Treatment
11.3.1 Market Overview
11.3.2 Medication
11.3.3 Surgery
11.3.4 Others
11.4 Hepatic Encephalopathy Treatment Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Injectable
11.4.4 Intravenous
11.4.5 Rectal
11.4.6 Others
11.5 Hepatic Encephalopathy Treatment Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Homecare
11.5.4 Speciality Clinics
11.5.5 Others
11.6 Hepatic Encephalopathy Treatment Market by Distribution Channels
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Hepatic Encephalopathy Treatment Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Hepatic Encephalopathy Treatment Market
12.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023)
12.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
12.3 Hepatic Encephalopathy Treatment Market by Drug Class
12.4 Hepatic Encephalopathy Treatment Market by Treatment
13 EU-4 and United Kingdom Hepatic Encephalopathy Treatment Market
13.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023)
13.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
13.3 Germany Hepatic Encephalopathy Treatment Market Overview
13.3.1 Hepatic Encephalopathy Treatment Market by Drug Class
13.3.2 Hepatic Encephalopathy Treatment Market by Treatment
13.4 France Hepatic Encephalopathy Treatment Market Overview
13.4.1 Hepatic Encephalopathy Treatment Market by Drug Class
13.4.2 Hepatic Encephalopathy Treatment Market by Treatment
13.5 Italy Hepatic Encephalopathy Treatment Market Overview
13.5.1 Hepatic Encephalopathy Treatment Market by Drug Class
13.5.2 Hepatic Encephalopathy Treatment Market by Treatment
13.6 Spain Hepatic Encephalopathy Treatment Market Overview
13.6.1 Hepatic Encephalopathy Treatment Market by Drug Class
13.6.2 Hepatic Encephalopathy Treatment Market by Treatment
13.7 United Kingdom Hepatic Encephalopathy Treatment Market Overview
13.7.1 Hepatic Encephalopathy Treatment Market by Drug Class
13.7.2 Hepatic Encephalopathy Treatment Market by Treatment
14 Japan Hepatic Encephalopathy Treatment Market
14.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023)
14.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
14.3 Hepatic Encephalopathy Treatment Market by Drug Class
14.4 Hepatic Encephalopathy Treatment Market by Treatment
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Salix Pharmaceuticals
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Mallinckrodt plc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Merck & Co., Inc.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Bausch Health
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Takeda Pharmaceutical Company Limited
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Johnson & Johnson Services, Inc.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Eisai Co., Ltd
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 AbbVie Inc.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Hikma Pharmaceuticals PLC
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Vedanta Biosciences
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Patricia Bloom
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Umecrine Cognition
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Axcella Health Inc.
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifictions
21.14 Pfizer Inc.
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Rebiotix
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Hepatic Encephalopathy Treatment Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings